The low rates of hepatitis C virus (HCV) screening in real-world practice indicate the existence of barriers that need to be overcome. In addition to the COVID-19 pandemic causing delays and/or discontinuations in many hepatitis elimination efforts, there are barriers on the provider level, such as communication challenges, low awareness of HCV, and poor knowledge of HCV screening recommendations. Patient-level barriers include lack of knowledge and awareness of HCV infection, confusion about transmission, and lack of insurance to pay for screening. It is essential that clinicians who treat patients with HCV are aware of these barriers and are equipped with strategies to overcome them in order to ensure screening and optimal management of all populations at risk for HCV infection.
This CMEO BriefCase will introduce a complex HCV case involving a patient with HCV and chronic kidney disease (CKD). Join Drs. Nancy Reau and Anthony Martinez as they dive deeper into treatment and management considerations for such patients, focusing on screening, diagnosis, and risk factors as well as the epidemiology and shared pathobiology of HCV and CKD.
At the end of this CME/CE activity, participants should be able to:
Implement CDC screening guidelines in practice to improve the detection and diagnosis of HCV.
Supported by an educational grant from Gilead Sciences, Inc.
U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reau reports the following financial relationships: Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept; and Merck; Grants/Research Support: Genfit; Intercept; and Shire.
Dr. Martinez reports the following financial relationships: Advisory Board: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept Consultant: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept Research Support: AbbVie Inc. and Gilead Sciences, Inc. Speakers Bureau: AbbVie Inc.; Eisai; and Gilead Sciences, Inc.
Dr. Lim (Reviewer/Advisor) reports the following financial relationships: Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics
Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
Kellie Busby, PharmD (planning committee)
Janan Sarwar, PharmD (planning committee)
Susan Perry (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).